Search academic texts

Information × Registration Number 0225U000776, (0124U003419) , R & D reports Title Determination of patterns of expression of cellular and molecular markers by lymphocytes and tumor cells for evaluation of antitumor immunity disorders in patients with acute myeloid leukemia. popup.stage_title Вивчити кореляційні взаємозв'язки між тривалістю періоду ремісії у хворих на гостру мієлоїдну лейкемію і вмістом в периферичної крові моноцитів, що експресують костимуляторні молекули CD80, CD86, а також Т-лімфоцитами, що несуть рецептор CD28. Head Hordiienko Alla I., Доктор біологічних наук Registration Date 18-01-2025 Organization State Institution "National Research Center for Radiation Medicine, Hematology and Onkology of the National Academy of Medical Sciences of Ukraine" popup.description1 To study the expression levels of CD3+ T lymphocytes of the CD28 receptor, as well as CD34+, CD117+ tumor cells of ligands CD80, CD86 to assess their role in the violation of antitumor immunity in patients with acute myeloid leukemia. popup.description2  Research Object – 109 patients with acute myeloid leukemia (AML) in the first acute phase before and after specific treatment, as well as patients with myelodysplastic syndrome before and after treatment. The aim - To investigate the intensity of CD28 receptor expression on CD3+ T-lymphocytes and co-stimulatory molecules of the B7 family (B7.1/CD80, B7.2/CD86) on tumor cell clones and monocytes; to examine indicators of adaptive and innate immunity, as well as clinical and hematological features in patients with acute myeloid leukemia during the first acute phase before treatment and after specific therapy. Research Methods – General clinical methods, immunophenotyping (flow cytometry), cytological, cytogenetic, and statistical methods. It has been established that patients with acute myeloid leukemia before treatment demonstrate a low level of expression intensity of co-stimulatory molecules of the B7 family (B7.1/CD80, B7.2/CD86) on peripheral blood tumor cells with an immunophenotypic profile of CD34+, CD117+, CD33+. It has been shown that in AML patients prior to treatment, there is an increased number of CD3+ T-lymphocytes with a low level of CD28+ ligand co-expression in peripheral circulation, which disrupts the intensity of immune responses. CD33+ monocytes with high levels of co-stimulatory molecule expression (CD80+, CD86+) and T-lymphocytes with CD28+ ligands detected in peripheral blood are positive factors for controlling remission duration.It has been demonstrated that one of the causes of antigen-specific antitumor immunity imbalance in AML patients before therapy is a decrease in the number of CD3+, CD3+CD4+, and CD3+CD8+ T-lymphocytes in peripheral blood. The study also revealed the heterogeneity of quantitative (monosomies, trisomies, and marker chromosomes) and structural (balanced and unbalanced) chromosomal abnormalities, both at diagnosis and during AML relapses. Medical and social effect. Medicine. Product Description popup.authors Aladieva Olena M. Andreieva Svitlana V. Korets Kateryna V. Starodub Halyna S. Tretiak Nataliia M. popup.nrat_date 2025-01-18 Close